Adult Dosing

Infections; burn wounds

• Cream:
• Apply cream qd-bid in a thickness of 1/16 inch to cleansed debrided areas
• Apply with a sterile gloved hand
• May/may not use dressings. However, if a dressing is necessary, apply only a thin layer
• Continue treatment until healing is progressing well or until the burn site is ready for grafting

• Solution:
• Apply 5% sol q6-8 hrs or PRN to keep dressing wet
• Cover grafted area with 1 layer of fine mesh. Cut an 8-ply dressing to the size of the graft and wet with 5% solution using an irrigation syringe and/or irrigation tubing. If irrigation tubing not used, moisten the gauze dressing q6-8 hrs or as needed
• Continue until autograft vascularization occurs and healing progresses (typically occurring in about 5 days)

Pediatric Dosing

• Note: Safety and effectiveness in pediatric patients <3 months have not been established [CRE]

Infections; burn wounds

Children >3 mo

• Cream:
• Apply cream qd-bid in a thickness of 1/16 inch to cleansed debrided areas
• Apply with a sterile gloved hand
• May/may not use dressings. However, if a dressing is necessary, apply only a thin layer
• Continue treatment until healing is progressing well or until the burn site is ready for grafting

• Solution:
• Apply 5% sol q6-8 hrs or PRN to keep dressing wet
• Cover grafted area with 1 layer of fine mesh. Cut an 8-ply dressing to the size of the graft and wet with 5% solution using an irrigation syringe and/or irrigation tubing. If irrigation tubing not used, moisten the gauze dressing q6-8 hrs or as needed
• Continue until autograft vascularization occurs and healing progresses (typically occurring in about 5 days)

• Adjunct in 2nd and 3rd degree burns [Cream]
• Adjunct to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds [Solution]

• Known hypersensitivity to mafenide

• N/A

Renal Dose Adjustment

• Renal impairment: Use with caution; monitor acid base balance closely. Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

See Supplemental Patient Information

• May cause metabolic acidosis; close monitoring of acid base balance is necessary (esp. with extensive 2nd degree or partial thickness burns, pulmonary or renal impairment)
• Masked hyperventilation with resulting respiratory alkalosis has occurred
• May cause pain/burning sensation, rash, pruritis, erythema, skin maceration (from prolonged wet dressings)

Cautions: Use cautiously in

• Acute renal impirment
• Pulmonary dysfunction
• G-6PD deficiency
• Sulfite sensitivity
• Asthma

Supplemental Patient Information

• Advise patients to contact physican if condition worsens, if irritation occurs, or if hyperventilation occurs

Pregnancy Category:C

Breastfeeding: It is not known whether mafenide is excreted in breastmilk. Manufacturer recommends discontinuation of breastfeeding, or discontinuation of treatment (taking into account the importance of the drug to the mother).

• DERM: Pain on application/burning sensation, excoriation of new skin, bleeding of skin
• HYPERSENSITIVITY: Rash itching, facial edema, swelling, hive, blisters, erythema, eosinophilia
• RESP: Tachypnea/hyperventilation, decrease in arterial pCO₂
• METABOLIC: Acidosis, increase in serum chloride
• GI: Diarrhea
• HEMA: Coagulation disorder, hemolytic anemia, bone marrow depression

• Topical anti-infective; mechanism of action is unknown; works by reducing the bacterial population present in the avascular tissues of burns and permits spontaneous healing of deep partial-thickness burns
• Topical mafenide is delivered to burned tissue over a 4 hr period following application
• Metabolized by liver
• Renally excreted
• Half-Life: Unknown

US Trade Name(s)

• Sulfamylon

US Availability

mafenide (generic)

• PWDR for SOLN: 5%

Sulfamylon

• PWDR for SOLN: 5%
• CRE: 8.5%

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

Antimicrobials

Dermatologic Topical Agents

Antibiotics

Infectious Disease

Dermatologic Topical Agents

Antibiotics

Dermatologic

Dermatologic Topical Agents

Antibiotics